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The purpose of this study was to assess the potential prognostic and/or predictive value of the expression of cyclin D1, cyclin E, and
p21 protein in a series of 98 anal carcinomas (T1–4, N0–3) treated by radiotherapy with (51) or without (47) chemotherapy in one
institution. Correlation with Mib1 index and p53 expression was also investigated. Median follow-up for surviving patients was 124
months (range: 30–266). Immunohistochemical staining was performed on pretreatment biopsies, applying a standard ABC
technique for cyclin D1 (clone DSC6, DAKO, 1:300), cyclin E (clone 13A3, Novocastra, 1:100), p21
WAF/CIP1 (clone SX118, DAKO,
1:50), p53 (clone DO7, DAKO, 1:200), and Mib1 (Ki-67, Dianova, 1:20). Tumours were classified into low- or high-expression
groups according to the expression level of the protein considered. High expression was found in 51% of tumours for cyclin E, in
33.7% for cyclin D1, and in 65% for p21. None of those factors were significantly associated with clinical variables such as advanced T
or N categories. In a monovariate analysis, advanced T and N categories and longer overall treatment time were the only variables
that correlated significantly with low rate of local control (LC) and disease-free survival. However, in a subgroup analysis, high p21
expression correlated with a trend for significantly higher 5-year LC (87 vs 68%, P¼0.07) in the N0 patients. The results of this study
suggest that the cell-cycle proteins investigated are unlikely to be clinically useful in predicting treatment response or prognosis in
patients with anal carcinomas.
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In anal carcinomas, indicators of patient outcome have traditionally
been derived from clinical features, including tumour size/
stage, extent of lymph node involvement, and anatomical subsite
(Cummings et al, 1991; Touboul et al, 1994; Allal et al, 1997). However,
despite careful evaluation of these factors, it is not possible to reliably
predict the outcome in individual patients. Anal carcinomas are
essentially a loco-regional disease, in which the success of treatment
depends mainly upon obtaining local and regional control. While
sphincter-conserving approaches yield an appreciable cure rate,
loco-regional failure may occur in up to 30–35% of patients
(Cummings et al, 1991; UKCCCR Anal Cancer Trial, 1996). Thus,
identification of new prognostic factors for local–regional control,
particularly biological parameters, may allow development of
individualised strategies that lead to improved results.
Recently, there has been great interest in tumour proliferation
and its relation to disease outcome (Begg et al, 1990; Lochrin et al,
1992). Besides markers of tumour cell kinetics (tritiated thymidine
labelling, S-phase fraction, various proliferation-associated antigens,
etc.), studies are now focusing on key elements that regulate cell-
cycle progression. Different checkpoints such as the restriction
point R in early G1, G1/S, and G2/M transitions are regulated
positively by a family of cyclin-dependent kinases (CDKs) and their
regulatory subunits, the cyclins (Bartek and Lukas, 2001). Cyclins D
and E are both involved in the sequential activation of various CDKs
(CDK4/6 for cyclin D and CDK2 for cyclin E), which, if the specific
CDK inhibitors are detached from the cyclin–CDK complexes,
allows phosphorylation of key substrates such as the retinoblastoma
protein and release of transcription factors like E2F. This control
system governs the passage of cells from G1 to S phase and initiation
of DNA replication (Bartkova et al, 1997; Kato, 1999). On the other
hand, the CDK inhibitors block cell-cycle transitions by inhibition
of the kinase activities of cyclin and CDK complexes. Two families
of CDK inhibitors have been identified, the p21
WAF1/CIP1 family
(p21
WAF1/CIP1,p 2 7
KIP1,p 5 7
KIP2) that inhibit a broad range of CDK–
cyclin complexes (Elledge and Harper, 1994), and the p16
INK4A
family (p16
INK4A,p 1 5
INK4B,p 1 8
INK4C,p 1 9
INK4D) that inhibit CDK4/6
complexes (Sherr and Roberts, 1995). p21 was the first mammalian
CDK inhibitor identified. In response to DNA damage, p21 is mainly
induced by wild-type p53 and is considered a mediator of the
tumour suppressor activity of p53 (el-Deiry et al, 1993).
The relation between cyclin/CDK inhibitor expression and
prognosis is still a matter of controversy. Cyclin E overexpression
was reported to be an indicator of poor outcome in several
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ltumours, including lung cancer (Muller-Tidow et al, 2001), non-
Hodgkin’s lymphoma (Ferreri et al, 2001), and breast cancer
(Keyomarsi et al, 2002). Data on the prognostic value of cyclin D
are rather rare, although overexpression was reported to be an
adverse factor in hypopharyngeal carcinomas (Nishimura et al,
1998). On the other hand, several studies have demonstrated that
underexpression of p21 protein is a negative prognostic marker in
different malignancies, including lung (Komiya et al, 1997), breast
(Wakasugi et al, 1997), bladder (Stein et al, 1998), and ovarian
cancers (Anttila et al, 1999). In anal carcinomas only one study has
been carried out, suggesting a negative impact of reduced
expression of p21 (Holm et al, 2001). To our knowledge, there
has been no previous study assessing the expression of cyclins D
and E and their relation with clinical–pathological parameters and
patient outcome in anal carcinomas. We studied the potential
prognostic and/or predictive value of the expression of cyclin D1,
cyclin E, and p21 in a large series of anal carcinomas treated by
radiotherapy (RT) with or without chemotherapy in one institu-
tion. Expression of these parameters was also correlated with the
proliferative index Mib1 and p53 expression.
PATIENTS AND METHODS
Patients and samples
The selection of patients for this study was based only on the
availability of adequate pretreatment paraffin blocks. Of 196
patients treated from January 1976 to November 1998, we were
able to collect 100 adequate embedded biopsy specimens. After
exclusion of two patients treated with brachytherapy alone, the
study group consisted of 98 patients. All pretreatment biopsies
were reviewed by an experienced pathologist (M-A B). All tumours
were classified according to the 1997 staging system of the Union
Internationale Contre le Cancer (UICC, 1997). Pretreatment
characteristics are shown in Table 1.
Treatment and follow-up
In all patients, treatment was delivered with curative intent at the
University Hospital of Geneva, according to schedules whose
details have previously been published (Allal et al, 1997). RT was
delivered in a split course, the first sequence consisting of wide-
field external-beam RT (EBRT, 30–40Gy) and the second of a
small-volume boost (EBRT or brachytherapy, 20–22Gy). The
median overall treatment time (OTT) was 72 days (range: 40–261).
Concomitant chemotherapy was administered to 51 patients
(52%). Generally chemotherapy started on day 1 and consis-
ted of one cycle of mitomycin C (10mgm
 2 intravenous bolus)
and a 5-day continuous infusion of 5-fluorouracil (600–
800mgm
 2day
 1). A total of 18 patients received a second course
of the same chemotherapy during the boost treatment.
Follow-up information was available for all patients except one, who
was lost for follow-up at 30 months without evidence of disease.
Information was collected from the medical records for recent patients,
while for earlier patients information was provided by their private
physician or by contacting the patients themselves. The median follow-
up for surviving patients was 124 months (range: 30–266).
Immunohistochemistry
Immunohistochemical studies were performed on pretreatment
biopsies, after review of all slides, to confirm the diagnosis of a
squamous cell carcinoma (either of large cell/keratinising, basaloid
or mixed type). Formalin-fixed and paraffin-embedded tissue
blocks were cut at 4mm and mounted on silane-coated glass slides.
Immunohistochemical stains were performed applying a standard
avidin–biotin complex (ABC) technique using the following
antibodies: cyclin D1 (clone DSC6, DAKO, 1:300), cyclin E (clone
13A3, Novocastra, 1:100), p21
WAF/CIP1 (clone SX118, DAKO, 1:50),
p53 (clone DO7, DAKO, 1:200), and Mib1 (Ki-67, Dianova, 1:20).
Heat-induced antigen retrieval was performed using a microwave
oven (600W, 3 5min) and citrate buffer (0.01M, pH6) for all
antibodies, except for p53, which was retrieved by using a pressure
cooker (3min). After cooling down and washing, slides were
incubated with the primary antibody for 30min at room tempera-
ture. Following another washing cycle, slides were incubated with
biotinylated secondary antibody (biotinylated rabbit anti-mouse
immunoglobulins, F(ab0)2, DAKO E0413) for 30min, and after
washing with a streptavidin–biotinylated-HRP complex (StreptAB-
Complexes, DAKO K0377). Slides were washed thoroughly, and then
incubated with diaminobenzidine used for visualisation.
Evaluation of immunohistochemical stains was carried out by
one of the authors (M-A B) blinded to patient outcome. Results
were assessed using a semiquantitative score based on the
estimated percentage of positive cells: 0¼0%; 1¼o5%; 2¼5–
50%; 3¼50–90%; and 4¼490%. Tumours were then classified
into two groups according to the level of expression of the protein
considered (low/negative¼low or high/positive¼high). Expres-
sion of p21 and p53 proteins was considered high if greater than
5% of the malignant cells were stained (score 2–4). For cyclin D1
and cyclin E, any tumour containing stained cells was considered
as high expression (scores 1–4), while for Mib-1 only tumours
with scores 3–4 were considered as high expression.
Statistical evaluation
The main end points for this study were local control (LC) and
disease-free survival (DFS). Tumour persistence or recurrence in
the anorectal area or the perineal skin was considered as events in
determining LC, whereas DFS additionally took into account
regional nodal recurrences as well as distant metastases. Actuarial
LC, overall and DFS rates were calculated by the product-limit
method. The time interval for the above-mentioned end points was
calculated from the first day of RT until the date of an event or of
the last follow-up. The logrank test was used to assess the
correlation of these end points with the expression of the cell-
cycle-related factors, the clinical (age, T stage, and N stage), and
therapeutic variables (addition of chemotherapy and OTT).
Fisher’s exact test (two-tailed) was used to evaluate differences
in proportions. A difference with a P-value of less than 0.05 was
considered significant.
Table 1 Patient characteristics (98)
No. of patients (%)
Median age, years (range) 68 (41–86)
Male/female (ratio) 22/76 (0.29)
Tumour location
Canal 7 anorectal junction 72 (73)
Margin 8 (8)
Canal+margin 18 (19)
Histologic type
Basaloid and transitional (small cells) 64 (65)
Keratinising squamous (large cells) 31 (32)
Mixed (large and small cells) 3 (3)
TN clinical classification (UICC 1997)
T1–2 60 (61)
T3–4 38 (39)
N0 74 (75)
N1–3 22 (23)
Nx 2 (2)
UICC¼Union International Contre le Cancer.
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Overall results
At the last follow-up, 50 patients were alive, 47 had died, and one
was lost to follow-up. In all, 34 patients presented with one or
more tumour-related events: 27 with persistent or recurrent local
disease, 13 with regional disease (four alone), and seven with
distant metastases (three alone). At 5 years, actuarial LC was 71%
(95% CI: 62–80%), actuarial DFS was 64% (95% CI: 54–74%) and
overall survival was 64% (95% CI: 54–73%).
Immunostaining and clinical–pathological correlations
The distribution of the percentage of cells stained for the different
factors studied is given in Table 2. High expression was found in
51% of tumours for cyclin E, in 34% for cyclin D1, in 65% for p21,
in 57% for p53 (Figure 1), and in 41% for Mib-1. Each factor was
assessed for potential association with the following clinical–
pathological parameters: age, sex, histological type, T category
(T1–2/T3–4), N category (N0/N1–3), and tumour subsite. Except
for an association of high Mib-1 with N1–3 category (P¼0.004), no
significant associations were found. On the other hand, assessment
of the association between the different pathobiological factors
showed a highly significant association of cyclin E with p21
expression (Po0.0001) and with p53 (P¼0.014). A significant
association of cyclin E with Mib-1 (P¼0.008) and a trend towards
an association with cyclin D1 expression (P¼0.09) were also found.
Moreover, a significant association was found between cyclin D1
and p53 (Po0.0001), while p21 expression was associated with
Mib-1 expression (P¼0.017). All the above associations were in the
same direction and no significant inverse correlation was found.
Univariate analysis
The results of the univariate analysis for LC and DFS using the
expression of the different pathobiological factors studied, as well
as the different clinical and therapeutic variables, are given in
Table 3. Advanced T and N categories, as well as longer OTT, were
the only variables that correlated significantly with low rate of LC
and DFS, while a trend for a significant correlation was observed
for high p53 expression and low DFS rate (P¼0.07). Since the
main aim of the study was to correlate the expression of cyclin E,
cyclin D1, and p21 with LC and DFS, and no significant association
with these factors was found in the univariate analysis, a
multivariate analysis was not carried out.
Figure 1 Results of immunohistochemical staining for 1¼cyclin D1, 2¼cyclin E, 3¼p21, and 4¼p53 in anal carcinomas. A large-cell carcinoma
((A)¼6561/77), a small cell type ((B)¼17386/78), and a carcinoma of mixed type ((C)¼7917/80) are illustrated.
Table 2 Distribution % of cells stained for the cell-cycle-related proteins
Proteins 0% 0–5% 5–50% 50–90% 490%
Cyclin D1 65 24 8 1 0
Cyclin E 48 25 24 1 0
p21 7 27 46 18 0
p53 1 41 44 11 1
Mib1 0 8 50 36 4
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In an attempt to define subgroups with wide differences in
outcome, we grouped patients according to the most significant
variables. The impact of each factor was studied after using
stratification by the other biological factors or by splitting by
clinical factors. By combining the different biological factors, no
particular subgroup was identified to be associated with LC or
DFS. According to the clinical subgroups, in the N0 category,
patients with high p21 expression had a trend for a significantly
higher 5-year LC (87%) compared to the group having low
p21 expression (68%) (P¼0.07). A similar result was observed
when studying DFS, with the respective rates of 80 and 63%
(P¼0.1). No clear correlation was observed when assessing the other
combinations.
DISCUSSION
As in cervical cancer, there is strong evidence that HPV
oncoproteins may be responsible for anal carcinogenesis (Frisch
et al, 1997; Clarke and Chetty, 2001). The ability of viral
oncoproteins to subvert cell-cycle checkpoints may constitute a
mechanism by which viral oncoproteins induce genetic instability
(Keating et al, 2001). HPV 16 E6 and E7 disrupt cell-cycle
checkpoints, particularly affecting by different mechanisms nearly
all CDK inhibitors linked to the G1 and G2 checkpoints (Galloway
and McDougall, 1996). The discovery that increased levels of cyclin
D1 and cyclin E promote cell growth by shortening the G1 phase
(Resnitzky et al, 1994) led to the postulation that overexpression of
those cyclins is positively involved in carcinogenesis and possibly
in clinical tumour aggressiveness. On the other hand, evidence that
p21 protein binds to and inhibits CDK–cyclin complexes, resulting
in cell-cycle arrest during the G1/S transition, was consistent with
the hypothesis that overexpression of this protein may be
associated with less aggressive tumours (Harper et al, 1993).
We found that anal carcinomas express cyclin D1 in 34% (45%
of cells stained) and cyclin E in 51% of cases. Since this report is
the first to evaluate those cyclins in this uncommon disease, no
useful comparison with the results of other series is possible.
Nevertheless, this expression is in line with the results reported in
lung cancer (Anton et al, 2000) and cervical cancer (Keating et al,
2001). High expression of p21 was found in 64% of specimens, in
accordance with the rate of 71% reported by Holm et al (2001) in a
similar series of anal carcinomas. In contrast with the series
reporting significant association between cyclin E expression and
tumour stage (in breast cancer; Keyomarsi et al, 2002) or p21
expression and histology (in anal cancer; Holm et al, 2001), in the
present series no association with the different clinical–patholo-
gical parameters was found. However, significant positive associa-
tions were observed between cyclin E and p21, p53 and Mib-1, as
well as between cyclin D and p53. Although the positive association
between cyclin E and Mib-1 (both related to proliferative activity)
was not unexpected, the highly significant positive association
between cyclin E and p21 was surprising, since their putative roles
in cell-cycle regulation are presumably antagonistic. Further
studies are required to determine whether these correlations
reflect the complex role these factors may play in cell-cycle
regulation or simply represent a spurious chance finding.
In the present study, we found no clear association between the
expression of cyclin D1, cyclin E, and p21 with patient outcome as
measured by LC and DFS. For completeness, the expression of p53
and Mib-1 was also included in our evaluation of cell-cycle-related
factors, although these factors have been discussed in prior reports
(Allal et al, 1997, 1998, 2002). Previous investigations of the
prognostic value of cyclin E levels by using immunohistochemical
techniques have produced conflicting results, for example, in
breast cancer (Porter et al, 1997; Donnellan et al, 2001) and lung
cancer (Anton et al, 2000; Muller-Tidow et al, 2001). However, the
majority of studies observed a positive correlation between
overexpression of cyclin E and poor outcome, including non-
Hodgkin’s lymphoma (Ferreri et al, 2001) and breast cancer
(Keyomarsi et al, 2002). Whether this observation reflects
publication bias to the detriment of negative studies remains
speculative. Nevertheless, when interpreting the results of any
retrospective study using immunostaining techniques, one should
acknowledge their inherent limitations, namely the effect of long-
term storage on molecular stability and the potential sampling bias
related to variations in expression throughout the tumour speci-
men, which may alter the findings and consequently the
conclusions.
Conflicting data were also reported concerning cyclin D1
expression, with overexpression associated with poor outcome in
Table 3 Univariate analysis of clinical, biological and therapeutic factors
No. of patients % 5-year local control P-value % 5-year DFS P-value
Age
p68/468 years 48/50 68/74 0.44 55/72 0.08
T category (UICC 1997)
T1–2/T3–4 60/38 81/55 0.006 73/49 0.01
N category
N0/N1–3 74/24 80/44 0.0003 74/33 o0.0001
Chemotherapy
No/yes 47/51 80/65 0.16 55/77 0.18
Overall treatment time
p72/472 days 50/48 84/58 0.008 77/50 0.004
Immunostaining (CI)
Cyclin E low/high 48/50 74 (62–87)/69 (55–82) 0.54 67 (53–81)/61 (47–75) 0.56
Cyclin D1 low/high 65/33 73 (62–84)/68 (51–84) 0.56 67 (55–78)/57 (39–75) 0.40
p21 low/high 34/64 66 (49–82)/74 (63–85) 0.46 59 (41–76)/66 (54–78) 0.50
p53 low/high 42/56 78 (66–91)/66 (53–79) 0.22 75 (62–88)/55 (42–69) 0.07
Mib-1 low/high 58/40 75 (64–86)/66 (51–81) 0.37 67 (54–80)/59 (44–75) 0.30
DFS¼disease-free survival, UICC¼Union International Contre le Cancer; CI¼confidence interval.
Cell-cycle factors in anal carcinoma
AS Allal et al
1242
British Journal of Cancer (2004) 91(7), 1239–1244 & 2004 Cancer Research UK
C
l
i
n
i
c
a
lhypopharyngeal carcinomas (Nishimura et al, 1998), while for lung
cancer cyclin D1 expression was reported to confer a better
prognosis (Anton et al, 2000). These results are consistent with the
as yet unclear role of cyclin D1 in cell proliferation processes.
Indeed, it has been demonstrated that high levels of cyclin D1
occurring at the G1/S-phase junction arrest S-phase entry (Pagano
et al, 1994), suggesting that the amount and timing of cyclin D1
can exert different effects on cellular proliferation. Thus, it seems
that in different situations cyclin D1 can be either a positive or
negative regulator of cellular proliferation.
The prognostic value of p21 expression has been reported by
many studies, showing that underexpression of p21 protein is a
negative prognostic marker in lung (Komiya et al, 1997), breast
(Wakasugi et al, 1997), bladder (Stein et al, 1998), ovarian (Anttila
et al, 1999), as well as in anal carcinomas (Holm et al, 2001). In our
analysis of the entire series, no significant difference was observed
in LC or DFS between subgroups of patients with tumours having
high or low p21 expression. However, in the subgroup of 74
patients without clinical nodal involvement, a trend for a better LC
and DFS was observed for tumours having high p21 expression.
While these results may be considered to confirm the findings of
Holm et al (2001), other studies have failed to reveal such a
correlation (Zhang et al, 1995; Pellikainen et al, 2003), suggesting
that the prognostic value of p21 still remains to be firmly
established.
In conclusion, our findings indicate that pretreatment tumour
expression of cyclin D1 and cyclin E has no apparent prognostic/
predictive value in anal carcinomas. Moreover, no clear correlation
was found between the expression of p21 protein and LC or DFS,
even though in one subgroup (N0 patients) overexpression of p21
was associated with a tendency towards a more favourable
outcome.
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